Artificial Intelligence in Pharmaceutical Development: Accelerating Formulation, Screening, and Approval

Menka Banchhor[1*]

[1]Rungta College of Pharmaceutical sciences and research (C G.), Chhattisgarh, India

*Corresponding Author E-mail: mbanchhor27@gmail.com

_____

Abstract:

Artificial Intelligence (AI) has rapidly become the backbone of modern pharmaceutical research, revolutionizing every phase of drug development—from target identification and compound screening to formulation design, clinical trials, and regulatory review. Traditional pharmaceutical R&D, which typically requires 10–15 years and billions of dollars, is being reimagined through machine learning (ML), deep learning (DL), and data-driven automation. This review comprehensively explores the integration of AI in pharmaceutical formulation, high-throughput screening, predictive toxicology, pharmacokinetic modeling, and regulatory decision-making. It highlights current technologies, case studies of AI-driven drug approvals, ethical considerations, and the future outlook of fully autonomous drug discovery pipelines.

Keywords: artificial intelligence, pharmaceutical development, drug discovery, formulation optimization, predictive modeling, regulatory science, machine learning.

1. Introduction

Conventional drug development has long been recognized as a slow, costly, and high-risk endeavor. On average, only about 10% of drug candidates that enter clinical trials ultimately achieve regulatory approval, while the rest are terminated due to inefficacy, toxicity, or unforeseen complications [1]. The financial burden is equally staggering: the cost of bringing a single drug to market often exceeds $2.5 billion, factoring in research,

development, and the expenses associated with failed candidates [2]. This process follows a rigid, sequential pathway—beginning with target identification, followed by preclinical testing, formulation development, phased clinical trials, and regulatory review. Each step is laden with uncertainties, human biases, and inefficiencies, making the entire pipeline both resource-intensive and prone to delays that can span over a decade. Consequently, the traditional model struggles to keep pace with the growing demand for innovative therapies, particularly for complex or rare diseases [3]. Artificial intelligence (AI) has emerged as a transformative force capable of addressing these bottlenecks by leveraging vast biomedical datasets and predictive modeling [4]. Unlike conventional methods, AI algorithms can analyze complex biological, chemical, and clinical data at unprecedented speed, uncovering patterns that might elude human researchers. From predicting molecular interactions and optimizing drug formulations to designing adaptive clinical protocols, AI is reshaping every phase of the pharmaceutical pipeline [5]. Industry leaders such as Pfizer, Novartis, and Roche have already integrated AI-based platforms into their workflows, demonstrating that these systems can emulate the decision-making processes of scientists—while operating faster, more consistently, and without fatigue [6]. The ability to rapidly generate insights and guide experimental design has positioned AI not merely as a supporting tool but as a central driver of innovation in modern drug discovery. Once regarded with skepticism and often dismissed as science fiction, AI has now established its credibility through tangible successes [7]. Notable examples include Exscientia's DSP-1181, an AI-designed molecule that advanced to human trials in record time, and Insilico Medicine's fibrosis candidate, which similarly benefited from AI-guided design [8]. These milestones underscore a shift from speculative promise to practical utility, highlighting the capacity of AI to accelerate development timelines, reduce costs, and improve the likelihood of clinical success. The evolving landscape demonstrates that AI is not merely an ancillary technology but a strategic asset that can redefine the pace, efficiency, and creativity of pharmaceutical innovation [9].

2. AI in Early-Stage Drug Discovery

The foundation of successful drug discovery lies in accurately identifying and validating therapeutic targets. Traditionally, this process has relied heavily on experimental assays and literature mining, which are time-consuming and often limited in scope [10]. AI has revolutionized this stage by employing machine learning models to analyze vast genomic, proteomic, and interactomic datasets, enabling researchers to uncover previously unrecognized drug targets. For instance, DeepMind's AlphaFold2 has dramatically improved the accuracy of protein structure predictions, offering detailed insights into ligand–receptor interactions that were once difficult or impossible to obtain experimentally [11]. This enhanced structural understanding accelerates both the identification of viable targets and the design of compounds with optimal binding properties,

reducing the trial-and-error approach historically associated with early-stage drug discovery. Once potential targets are identified, the next challenge is discovering compounds that can effectively modulate those [12]. Deep generative models, such as Generative Adversarial Networks (GANs) and variational autoencoders, have transformed this step by designing novel molecules with specific pharmacophoric characteristics. These AI-driven approaches allow virtual screening of millions—or even billions—of compounds in silico, drastically reducing the need for costly and labor-intensive wet-lab experiments [13]. As summarized in Table 1, AI-driven screening not only expands the number of compounds evaluated but also accelerates timelines and improves hit rates compared to traditional methods [14]. **(Table 1)**

Table 1: Comparison between Traditional and AI-Driven Screening Approaches

Aspect	Traditional	AI-Driven	Reference
Screening size	$\sim10^4$ compounds	$>10^8$ compounds virtually	15
Duration	Months–years	Days–weeks	16
Hit rate	$\sim0.1\%$	Up to 10%	17
Cost	Very high	60–70% reduced	18

The stark contrast between conventional and AI-enabled screening highlights the transformative potential of machine learning in early-stage drug development, making the process faster, more cost-effective, and more productive [19]. Another critical advantage of AI lies in predicting a compound's pharmacokinetic and safety profiles—collectively referred to as ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity. Historically, these properties were assessed late in the development pipeline through animal models and early human trials, contributing to high attrition rates [20]. AI models, however, can forecast ADMET characteristics at the virtual screening stage, enabling researchers to prioritize molecules with favorable profiles while discarding likely failures early on. This preemptive evaluation not only saves significant time and resources but also reduces the ethical and financial burdens associated with extensive animal testing. Collectively, these AI-driven advancements are reshaping early-stage drug

Research Journal of Advanced Multidisciplinary Insights (RJAMI)
ISSN: Applied | Vol. 01 Issue 01, July-Dec 2025 | pp. 49-64

51

discovery, allowing scientists to move from hypothesis to candidate selection with unprecedented efficiency and precision [21].

1. **AI in Pharmaceutical Formulation Development**

   Formulation development has traditionally been a labor-intensive and iterative process, requiring extensive trial-and-error experiments to achieve the desired drug performance. Today, artificial intelligence is transforming this landscape by enabling data-driven optimization of formulations [22]. Machine learning (ML) models can analyze vast historical datasets, including excipient compatibility, stability outcomes, and dissolution profiles, to predict the most promising combinations. This approach significantly reduces the number of experiments needed, shortens development timelines, and enhances the likelihood of achieving stable, effective, and patient-compliant formulations. By leveraging AI, formulation scientists can now make informed decisions that balance efficacy, manufacturability, and shelf-life, all while minimizing resource consumption and experimental uncertainty [23]. Several AI and ML techniques have proven particularly effective in pharmaceutical formulation development. Random Forest (RF) models are widely employed to predict solubility and particle size distributions, helping optimize the physical characteristics of dosage forms [24]. Support Vector Machines (SVM) assist in selecting the most suitable polymorphic forms of active pharmaceutical ingredients (APIs), a critical factor affecting stability and bioavailability. For complex, non-linear relationships between drugs and excipients, Artificial Neural Networks (ANN) provide accurate predictions, capturing subtle interactions that traditional statistical methods often miss [25]. Meanwhile, Deep Learning (DL) algorithms are increasingly used for automated prediction of drug release kinetics, shelf-life, and other critical quality attributes, enabling highly precise and scalable formulation design. Together, these techniques provide a comprehensive toolkit for modern formulation scientists to innovate efficiently [26].

Beyond individual algorithms, integrated platforms now allow end-to-end "smart" formulation development. Systems like AstraZeneca's MODDE and TIBCO Statistica combine design of experiments (DoE) with machine learning, creating adaptive, self-optimizing formulations [27]. These platforms can iteratively refine formulation parameters in silico, simulating multiple scenarios and predicting outcomes before a single laboratory experiment is performed. The result is a dramatic reduction in development time, increased reproducibility, and the ability to tailor formulations to specific patient needs or manufacturing constraints [28]. By embedding AI directly into the formulation workflow, pharmaceutical companies are not only improving efficiency but also opening the door to more personalized, high-performance medicines. **(**Figure 1)

Figure 1: Workflow of AI-Assisted Formulation Design.

Research Journal of Advanced Multidisciplinary Insights (RJAMI)
ISSN: Applied | Vol. 01 Issue 01, July-Dec 2025 | pp. 49-64

52

The convergence of artificial intelligence and nanotechnology is opening new frontiers in precision drug delivery. Nanoparticle-based formulations, including liposomes, polymeric nanoparticles, and solid lipid carriers, offer enhanced bioavailability, targeted delivery, and controlled release [29]. However, optimizing their properties—such as polymer ratios, particle size distribution, zeta potential, and encapsulation efficiency—has traditionally been a complex, trial-and-error process. AI is now transforming this space by providing predictive models that can forecast these critical parameters with remarkable accuracy [30]. For instance, convolutional neural networks (CNNs) are employed to analyze transmission electron microscopy (TEM) images, enabling real-time classification of nanoparticle morphology and size. This capability allows formulation scientists to rapidly fine-tune preparation conditions and polymer compositions, ensuring reproducible and high-performance nanocarriers [31]. By integrating AI into nanotechnology workflows, researchers can accelerate the design of next-generation drug delivery systems, reduce experimental waste, and move closer to truly personalized therapeutic solutions [32].

4.1 Patient recruitment and trial design

Patient recruitment and trial design are among the most time-consuming and expensive stages of clinical development. Traditional recruitment methods often rely on manual chart reviews, physician referrals, and outreach campaigns, leading to significant delays and high dropout rates [33]. AI is revolutionizing this process by leveraging electronic health records (EHRs), genomic data, and other clinical datasets to identify eligible participants with precision. Systems like IBM Watson can analyze complex patient profiles, matching individuals to clinical trials based on both

genetic markers and broader clinical eligibility criteria [34]. This targeted approach not only accelerates recruitment timelines—reducing them by as much as 80% in some cases—but also improves the likelihood of enrolling patients who are most likely to benefit from the intervention, enhancing trial efficiency and outcome reliability. Another critical challenge in clinical development is predicting how patients will respond to novel therapies [35]. Reinforcement learning and other advanced AI models enable the simulation of patient responses across varying dosages, treatment schedules, and clinical conditions. By modeling these scenarios in silico, researchers can identify optimal dosing regimens, anticipate adverse reactions, and refine trial protocols before actual patient exposure [36]. This proactive strategy reduces the risk of late-stage failures, improves patient safety, and helps design more efficient, cost-effective trials. Beyond controlled trials, post-marketing surveillance and real-world evidence (RWE) provide valuable insights into drug performance in broader patient populations [37]. AI systems can integrate data from wearable devices, health apps, and electronic medical records to continuously monitor safety, efficacy, and adherence. This integration enables adaptive trial frameworks, where ongoing patient data can dynamically inform dosing adjustments, safety interventions, and trial modifications. Such AI-driven adaptive approaches bridge the gap between clinical research and real-world application, allowing pharmaceutical companies to maintain continuous feedback loops that enhance drug safety, efficacy, and patient-centric outcomes [38].

5. Regulatory Applications and AI-Driven Approval Pathways

Regulatory authorities worldwide are increasingly recognizing the potential of artificial intelligence to enhance the efficiency, accuracy, and transparency of drug approval processes. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are actively encouraging AI-driven methodologies through initiatives like the FDA's *Digital Health Innovation Action Plan* and EMA's *Big Data Taskforce* [39]. These programs aim to establish frameworks for evaluating AI-based tools, promoting data-driven decision-making, and facilitating faster, safer approval pathways. By integrating AI into regulatory workflows, authorities can leverage predictive analytics, automated data review, and advanced risk assessments to complement traditional evaluation methods, ultimately accelerating access to innovative therapies without compromising patient safety [40]. Toxicity assessment has traditionally relied on extensive in vitro and in vivo studies, which are time-consuming, costly, and ethically challenging due to animal use. AI models are now changing this landscape by predicting toxicological profiles directly from molecular structures. Tools like DeepTox and TOX21, approved and recognized by the FDA, can forecast carcinogenic, mutagenic, and other toxic effects with high accuracy [41]. By identifying potentially hazardous compounds early in the development pipeline, these models reduce the need for animal testing, lower attrition rates, and allow researchers to focus resources on the most promising candidates. Predictive toxicology not only

Research Journal of Advanced Multidisciplinary Insights (RJAMI)
ISSN: Applied | Vol. 01 Issue 01, July-Dec 2025 | pp. 49-64

54

accelerates safety evaluation but also aligns with global efforts to minimize animal experimentation in pharmaceutical research 42. Regulatory submissions involve compiling extensive datasets, generating risk-benefit analyses, and ensuring consistency across multiple sections of the dossier—a process traditionally prone to human error and inefficiency. Artificial intelligence, particularly Natural Language Processing (NLP) systems, is transforming regulatory documentation by automating these tasks [43]. NLP algorithms can summarize large volumes of experimental data, highlight discrepancies, generate coherent risk-benefit reports, and even cross-check regulatory requirements in real time. This automation streamlines dossier preparation, reduces review times, and supports regulators in making more informed, data-driven decisions. Collectively, AI-driven regulatory tools are ushering in a new era where drug approval pathways are faster, more precise, and better aligned with modern computational capabilities [44]. (Table 2)

Table 2: AI Implementations in Regulatory Science

Organization	System	Function	Impact	Reference
FDA	DeepTox, Predictive AI	Toxicology, approval forecasting	Reduced review time	45
EMA	Big Data Analytics Platform	Clinical outcome prediction	Data-driven decision making	46
WHO	AI-Pharma Watch	Post-market surveillance	Early signal detection	47

6. Case Studies of AI-Driven Drug Development

Artificial intelligence has already demonstrated a tangible impact across multiple stages of drug development, from early discovery to clinical optimization and rapid vaccine design. A number of high-profile examples highlight the transformative potential of AI in pharmaceutical research [48]. Exscientia, a UK-based company, employed its CentaurChem platform to design the molecule DSP-1181, a treatment for obsessive-compulsive disorder, advancing it to Phase I clinical trials

Research Journal of Advanced Multidisciplinary Insights (RJAMI)
ISSN: Applied | Vol. 01 Issue 01, July-Dec 2025 | pp. 49-64

55

within just 12 months—an achievement that would traditionally take several years [49]. Similarly, Insilico Medicine utilized its Chemistry42 platform to develop the fibrosis candidate INS018_055, which also progressed rapidly to Phase I trials, demonstrating AI's ability to accelerate target-to-clinic timelines. In addition to novel drug discovery, AI has proved invaluable in drug repurposing. BenevolentAI leveraged its Knowledge Graph AI to identify Baricitinib, originally approved for rheumatoid arthritis, as a potential treatment for COVID-19—pinpointing the candidate in only 48 hours, well ahead of conventional approaches [50]. Meanwhile, Pfizer incorporated IBM Watson into its clinical development strategy for Palbociclib, a breast cancer therapy, enabling faster trial design and more precise patient matching. The synergy between AI and innovative modalities is also evident in vaccine development: Moderna applied AI-driven mRNA design tools to optimize antigens for the COVID-19 vaccine, significantly shortening development timelines and contributing to its rapid approval [51]. These case studies collectively illustrate how AI is no longer a theoretical concept but a practical, results-driven force in drug development. By enhancing efficiency, reducing costs, and enabling rapid iteration, AI platforms are redefining what is achievable in pharmaceutical innovation—from accelerating molecule design to facilitating pandemic responses and personalized medicine [52].

7. Ethical, Legal, and Societal Considerations

Artificial intelligence in drug development depends heavily on access to vast datasets, including sensitive patient health records, genomic sequences, and proprietary molecular libraries. While these data are invaluable for training predictive models, they raise serious concerns regarding privacy and security [53]. Compliance with regulations such as the General Data Protection Regulation (GDPR) in Europe, the Health Insurance Portability and Accountability Act (HIPAA) in the United States, and other local data protection laws is essential. Pharmaceutical companies must implement robust data anonymization, secure storage, and controlled access protocols to ensure that patient confidentiality is never compromised. Furthermore, transparent communication with patients and participants about data usage fosters trust and aligns AI-driven research with ethical standards [54]. Another critical challenge is the potential for algorithmic bias. AI models are only as unbiased as the data on which they are trained, and if datasets reflect historical inequities, the resulting predictions and recommendations may inadvertently propagate healthcare disparities. For example, underrepresentation of certain populations in clinical trial data could lead to AI algorithms that underpredict adverse effects or efficacy in these groups [55]. Addressing this issue requires the development of explainable AI (XAI) frameworks that provide transparency into decision-making processes, enabling researchers and regulators to identify, correct, and mitigate bias. Prioritizing interpretability and fairness is essential to ensure equitable healthcare outcomes across diverse populations [56]. AI-driven drug discovery also introduces legal complexities surrounding intellectual property. Determining authorship and patent ownership of molecules or

formulations generated autonomously by AI systems remains ambiguous under current laws. Questions arise regarding whether the AI developer, the pharmaceutical company, or the AI itself should hold patent rights, and how to define inventive contribution in the context of machine-generated designs [57]. Resolving these issues is critical for incentivizing innovation while maintaining a fair and transparent IP framework. As AI continues to reshape pharmaceutical research, clear legal guidance and international consensus will be necessary to navigate these emerging challenges, balancing innovation with accountability and societal benefit [58].

8. Future Directions

The concept of patient-specific digital twins is poised to revolutionize personalized medicine. These virtual replicas integrate an individual's genomic, proteomic, metabolic, and clinical data to simulate drug responses in silico, enabling researchers and clinicians to predict efficacy, optimize dosing, and anticipate adverse effects before actual administration [59]. By providing a dynamic, virtual testing ground, digital twins can dramatically reduce trial-and-error approaches, enhance patient safety, and guide truly individualized therapy strategies, transforming how treatments are designed and delivered. The integration of AI with advanced robotics is giving rise to fully autonomous laboratories, sometimes called "self-driving labs." These cloud-connected systems can automate complex workflows, including chemical synthesis, formulation testing, and high-throughput screening, while continuously recording and analyzing experimental data in real time [60-61]. By eliminating manual intervention, autonomous labs increase reproducibility, accelerate discovery timelines, and allow researchers to explore a far broader chemical and biological space than traditional methods permit. The convergence of quantum computing and AI promises unprecedented accuracy in molecular modeling. Quantum-AI hybrids are capable of simulating molecular interactions at the atomic level, accounting for complex quantum phenomena that classical computers cannot efficiently handle [62]. This capability can transform structure-based drug design, enabling precise prediction of binding affinities, reaction mechanisms, and protein dynamics, ultimately improving the success rates of drug discovery and reducing reliance on expensive and time-consuming experimental validation. As AI becomes increasingly embedded in drug development, regulatory authorities are expected to require explainable AI (XAI) outputs that are both auditable and scientifically interpretable [63-64]. Future frameworks from agencies like the FDA will emphasize transparency, ensuring that AI-driven decisions—ranging from candidate selection to clinical trial design—can be justified with clear, evidence-based reasoning. This shift will not only enhance regulatory compliance but also build confidence among clinicians, patients, and stakeholders, promoting responsible adoption of AI in pharmaceutical innovation [65].

9. Conclusion

Artificial intelligence has fundamentally and irreversibly transformed pharmaceutical innovation, reshaping the way drugs are discovered, developed, and delivered. By merging computational power with chemical intuition, AI enables researchers to accelerate molecule design, optimize formulations, predict safety profiles, and streamline clinical trial processes, all while reducing costs and minimizing human error. Its influence spans every stage of the drug development pipeline—from early target identification and virtual screening to predictive ADMET profiling, smart formulation, clinical trial optimization, and regulatory compliance. Case studies from companies like Exscientia, Insilico Medicine, BenevolentAI, Pfizer, and Moderna demonstrate that AI is no longer a futuristic concept but a practical, results-driven tool capable of delivering real-world impact.

Looking forward, the pharmaceutical landscape is likely to evolve toward autonomous, AI-driven ecosystems, where robotic laboratories, digital twins, quantum-AI hybrids, and adaptive regulatory frameworks allow machines not only to assist but to lead complex discovery and formulation processes. Despite its promise, the successful integration of AI will depend on careful attention to regulatory adaptation, data privacy, algorithmic fairness, intellectual property, and explainability. Addressing these ethical, legal, and societal considerations will be critical to ensuring that AI-driven innovation remains safe, equitable, and transparent. Ultimately, the next decade may witness a technological renaissance in medicine, where the synergy of AI, computational modeling, and human expertise dramatically enhances the speed, precision, and personalization of pharmaceutical development, heralding a new era of patient-centric therapeutics.

References

1. Singh, D., Singh, R., Gehlot, A., et al. (2022). An imperative role of digitalization in monitoring cattle health for sustainability. *Electronics, 11*(2702). https://doi.org/10.3390/electronics11172702

2. Kalyane, D., Sanap, G., Paul, D., et al. (2020). Artificial intelligence in the pharmaceutical sector: Current scene and prospect. In *The future of pharmaceutical product development and research* (pp. 73–107). Elsevier.

3. Paul, D., Sanap, G., Shenoy, S., et al. (2021). Artificial intelligence in drug discovery and development. *Drug Discovery Today, 26*, 80–93. https://doi.org/10.1016/j.drudis.2020.10.010

4. Gao, M., Liu, S., Chen, J., et al. (2021). Potential of Raman spectroscopy in facilitating pharmaceutical formulations development—An AI perspective. *International Journal of Pharmaceutics, 597*, 120334. https://doi.org/10.1016/j.ijpharm.2021.120334

Research Journal of Advanced Multidisciplinary Insights (RJAMI)
ISSN: Applied | Vol. 01 Issue 01, July-Dec 2025 | pp. 49-64

58

5. Landin, M., & Rowe, R. C. (2013). Artificial neural network technology to model, understand, and optimize drug formulations. In *Formulation tools for pharmaceutical development* (pp. 7–37). Elsevier.

6. Al Kuwaiti, A., Nazer, K., Al-Reedy, A., et al. (2023). A review of the role of artificial intelligence in healthcare. *Journal of Personalized Medicine, 13*(951). https://doi.org/10.3390/jpm13060951

7. Duch, W., Swaminathan, K., & Meller, J. (2007). Artificial intelligence approaches for rational drug design and discovery. *Current Pharmaceutical Design, 13*, 1497–1508. https://doi.org/10.2174/138161207780765954

8. Blasiak, A., Khong, J., & Kee, T. (2020). CURATE.AI: Optimizing personalized medicine with artificial intelligence. *SLAS Technology, 25*, 95–105. https://doi.org/10.1177/2472630319890316

9. Baronzio, G., Parmar, G., & Baronzio, M. (2015). Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid. *Frontiers in Oncology.* https://doi.org/10.3389/fonc.2015.00165

10. Mishra, S. S., Behera, P. K., Kar, B., & Ray, R. C. (2018). Advances in probiotics, prebiotics, and nutraceuticals. *Innovations and technologies in the fermented food and beverage industry.* https://doi.org/10.1007/978-3-319-74820-7_7

11. Waring, M. J., Arrowsmith, J., Leach, A. R., et al. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. *Nature Reviews Drug Discovery, 14*, 475–486. https://doi.org/10.1038/nrd4609

12. Martin, L., Hutchens, M., Hawkins, C., & Radnov, A. (2017). How much do clinical trials cost? *Nature Reviews Drug Discovery, 16*, 381–382. https://doi.org/10.1038/nrd.2017.70

13. Mak, K.-K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and prospects. *Drug Discovery Today, 24*, 773–780. https://doi.org/10.1016/j.drudis.2018.11.014

14. Sellwood, M. A., Ahmed, M., Segler, M. H., & Brown, N. (2018). Artificial intelligence in drug discovery. *Future Medicinal Chemistry, 10*, 2025–2028. https://doi.org/10.4155/fmc-2018-0212

15. Petitjean, M., & Camproux, A. (2016). In silico medicinal chemistry: Computational methods to support drug design. *ChemMedChem, 11*, 1480–1481. https://doi.org/10.1002/cmdc.201600165

16. Zhang, L., Tan, J., Han, D., & Zhu, H. (2017). From machine learning to deep learning: Progress in machine intelligence for rational drug discovery. *Drug Discovery Today, 22*, 1680–1685. https://doi.org/10.1016/j.drudis.2017.08.010

17. Zhang, Y., Zhang, G., & Shang, Q. (2017). Computer-aided clinical trial recruitment based on domain-specific language translation: A case study of retinopathy of

prematurity. *Journal of Healthcare Engineering, 2017,* 1–9. https://doi.org/10.1155/2017/7862672

18. Zhu, H. (2020). Big data and artificial intelligence modeling for drug discovery. *Annual Review of Pharmacology and Toxicology, 60,* 573–589. https://doi.org/10.1146/annurev-pharmtox-010919-023324

19. Ciallella, H. L., & Zhu, H. (2019). Advancing computational toxicology in the big data era by artificial intelligence: Data-driven and mechanism-driven modeling for chemical toxicity. *Chemical Research in Toxicology, 32,* 536–547. https://doi.org/10.1021/acs.chemrestox.8b00393

20. Jain, N., Gupta, S., Sapre, N., & Sapre, N. S. (2015). In silico de novo design of novel NNRTIs: A bio-molecular modelling approach. *RSC Advances, 5,* 14814–14827. https://doi.org/10.1039/C4RA15478A

21. Wang, Y., Guo, Y., Kuang, Q., et al. (2015). A comparative study of family-specific protein–ligand complex affinity prediction based on a random forest approach. *Journal of Computer-Aided Molecular Design, 29,* 349–360. https://doi.org/10.1007/s10822-014-9827-y

22. Vyas, M., Thakur, S., Riyaz, B., et al. (2018). Artificial intelligence: The beginning of a new era in the pharmacy profession. *Asian Journal of Pharmacy, 12,* 72–76. https://doi.org/10.22377/ajp.v12i02.2317

23. Mintong, G., Gunjan, K., Wendy, W., et al. (2002). A prototype intelligent hybrid system for hard gelatin capsule formulation development. *Pharmaceutical Technology, 26,* 44–60.

24. Mehta, C. H., Narayan, R., & Nayak, U. Y. (2019). Computational modeling for formulation design. *Drug Discovery Today, 24,* 781–788. https://doi.org/10.1016/j.drudis.2018.11.018

25. Zhao, C., Jain, A., Hailemariam, L., et al. (2006). Toward intelligent decision support for pharmaceutical product development. *Journal of Pharmaceutical Innovation, 1,* 23–35. https://doi.org/10.1007/BF02784878

26. Rantanen, J., & Khinast, J. (2015). The future of pharmaceutical manufacturing sciences. *Journal of Pharmaceutical Sciences, 104,* 3612–3638. https://doi.org/10.1002/jps.24594

27. Ketterhagen, W. R., Am Ende, M. T., & Hancock, B. C. (2009). Process modeling in the pharmaceutical industry using the discrete element method. *Journal of Pharmaceutical Sciences, 98,* 442–470. https://doi.org/10.1002/jps.21466

28. Chen, W., Desai, D., Good, D., et al. (2016). Mathematical model-based accelerated development of extended-release metformin hydrochloride tablet formulation. *AAPS PharmSciTech, 17,* 1007–1013. https://doi.org/10.1208/s12249-015-0423-9

29. Huang, Z., Juarez, J. M., & Li, X. (2017). Data mining for biomedicine and healthcare. *Journal of Healthcare Engineering, 2017*, 1–2. https://doi.org/10.1155/2017/7107629

30. Mamoshina, P., Vieira, A., Putin, E., & Zhavoronkov, A. (2016). Applications of deep learning in biomedicine. *Molecular Pharmaceutics, 13*, 1445–1454. https://doi.org/10.1021/acs.molpharmaceut.5b00982

31. Seddon, G., Lounnas, V., McGuire, R., et al. (2012). Drug design forever, from hype to hope. *Journal of Computer-Aided Molecular Design, 26*, 137–150. https://doi.org/10.1007/s10822-011-9519-9

32. Schneider, G. (2018). Automating drug discovery. *Nature Reviews Drug Discovery, 17*, 97–113. https://doi.org/10.1038/nrd.2017.232

33. Klopman, G., Chakravarti, S. K., Zhu, H., et al. (2004). ESP: A method to predict toxicity and pharmacological properties of chemicals using multiple MCASE databases. *Journal of Chemical Information and Computer Sciences, 44*, 704–715. https://doi.org/10.1021/ci030298n

34. Menden, M. P., Iorio, F., Garnett, M., et al. (2013). Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. *PLoS ONE, 8*, e61318. https://doi.org/10.1371/journal.pone.0061318

35. Challa, S., & Potumarthi, R. (2013). Chemometrics-based process analytical technology (PAT) tools: Applications and adaptation in pharmaceutical and biopharmaceutical industries. *Applied Biochemistry and Biotechnology, 169*, 66–76. https://doi.org/10.1007/s12010-012-9950-y

36. Matthews, H., Hanison, J., & Nirmalan, N. (2016). "Omics"-informed drug and biomarker discovery: Opportunities, challenges and future perspectives. *Proteomes, 4*, 28. https://doi.org/10.3390/proteomes4030028

37. Merk, D., Friedrich, L., Grisoni, F., & Schneider, G. (2018). De novo design of bioactive small molecules by artificial intelligence. *Molecular Informatics, 37*, 1700153. https://doi.org/10.1002/minf.201700153

38. Hamet, P., & Tremblay, J. (2017). Artificial intelligence in medicine. *Metabolism, 69*, S36–S40. https://doi.org/10.1016/j.metabol.2017.01.011

39. Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011). Principles of early drug discovery. *British Journal of Pharmacology, 162*, 1239–1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x

40. Katsila, T., Spyroulias, G. A., Patrinos, G. P., & Matsoukas, M.-T. (2016). Computational approaches in target identification and drug discovery. *Computational and Structural Biotechnology Journal, 14*, 177–184. https://doi.org/10.1016/j.csbj.2016.04.004

41. Mohs, R. C., & Greig, N. H. (2017). Drug discovery and development: Role of basic biological research. *Alzheimer's & Dementia: Translational Research & Clinical Interventions, 3*, 651–657. https://doi.org/10.1016/j.trci.2017.10.005

42. Emig, D., Ivliev, A., Pustovalova, O., et al. (2013). Drug target prediction and repositioning using an integrated network-based approach. *PLoS ONE, 8*, e60618. https://doi.org/10.1371/journal.pone.0060618

43. Vora, L. K., Gholap, A. D., Jetha, K., et al. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics, 15*, 1916. https://doi.org/10.3390/pharmaceutics15071916

44. Chen, Y., McCall, T. W., Baichwal, A. R., & Meyer, M. C. (1999). The application of an artificial neural network and pharmacokinetic simulations in the design of controlled-release dosage forms. *Journal of Controlled Release, 59*, 33–41. https://doi.org/10.1016/S0168-3659(98)00171-0

45. Kesavan, J. G., & Peck, G. E. (1996). Pharmaceutical granulation and tablet formulation using neural networks. *Pharmaceutical Development and Technology, 1*, 391–404. https://doi.org/10.3109/10837459609031434

46. Colbourn, E., & Rowe, R. (1996). Modelling and optimization of a formulation using neural networks and genetic algorithms. *Pharmaceutical Technology Europe, 8*, 46–55.

47. Wilson, W. I., Peng, Y., & Augsburger, L. L. (2005). Generalization of a prototype intelligent hybrid system for hard gelatin capsule formulation development. *AAPS PharmSciTech, 6*, E449–E457. https://doi.org/10.1208/pt060356

48. Sekiguchi, K., & Obi, N. (1961). Studies on the absorption of an eutectic mixture. I. A comparison of the behavior of the eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. *Chemical & Pharmaceutical Bulletin (Tokyo), 9*, 866–872. https://doi.org/10.1248/cpb.9.866

49. Huang, Y., & Dai, W.-G. (2014). Fundamental aspects of solid dispersion technology for poorly soluble drugs. *Acta Pharmaceutica Sinica B, 4*, 18–25. https://doi.org/10.1016/j.apsb.2013.11.001

50. Serajuddin, A. T. M. (1999). Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. *Journal of Pharmaceutical Sciences, 88*, 1058–1066. https://doi.org/10.1021/js980403l

51. Barmpalexis, P., Kachrimanis, K., & Georgarakis, E. (2011). Solid dispersions in the development of a nimodipine floating tablet formulation and optimization by artificial neural networks and genetic programming. *European Journal of Pharmaceutics and Biopharmaceutics, 77*, 122–131. https://doi.org/10.1016/j.ejpb.2010.09.017

52. Patel, T. B., Patel, L., Patel, T. R., & Suhagia, B. (2015). Artificial neural network as a tool for quality by design in formulation development of solid dispersion of fenofibrate. *Bulletin of Pharmaceutical Research, 5*, 20–27.

53. Barmpalexis, P., Koutsidis, I., Karavas, E., et al. (2013). Development of PVP/PEG mixtures as appropriate carriers for the preparation of drug solid dispersions by the melt mixing technique and optimization of dissolution using artificial neural networks. *European Journal of Pharmaceutics and Biopharmaceutics, 85*, 1219–1231. https://doi.org/10.1016/j.ejpb.2013.03.013

54. Han, R., Xiong, H., Ye, Z., et al. (2019). Predicting physical stability of solid dispersions by machine learning techniques. *Journal of Controlled Release, 311–312*, 16–25. https://doi.org/10.1016/j.jconrel.2019.08.030

55. Khan, B. A. (2011). Basics of pharmaceutical emulsions: A review. *African Journal of Pharmacy and Pharmacology*. https://doi.org/10.5897/AJPP11.698

56. Bagwe, R. P., Kanicky, J. R., Palla, B. J., et al. (2001). Improved drug delivery using microemulsions: Rationale, recent progress, and new horizons. *Critical Reviews in Therapeutic Drug Carrier Systems, 18*, 77–140.

57. McClements, D. J. (2012). Nanoemulsions versus microemulsions: Terminology, differences, and similarities. *Soft Matter, 8*, 1719–1729. https://doi.org/10.1039/C2SM06903B

58. Sarker, D. (2005). Engineering of nanoemulsions for drug delivery. *Current Drug Delivery, 2*, 297–310. https://doi.org/10.2174/156720105774370267

59. Solans, C., Izquierdo, P., Nolla, J., et al. (2005). Nano-emulsions. *Current Opinion in Colloid & Interface Science, 10*, 102–110. https://doi.org/10.1016/j.cocis.2005.06.004

60. Tenjarla, S. (1999). Microemulsions: An overview and pharmaceutical applications. *Critical Reviews in Therapeutic Drug Carrier Systems, 16*, 461–521.

61. Kumar, K., Panpalia, G., & Priyadarshini, S. (2011). Application of artificial neural networks in optimizing the fatty alcohol concentration in the formulation of an O/W emulsion. *Acta Pharmaceutica, 61*, 249–256. https://doi.org/10.2478/v10007-011-0013-7

62. Gašperlin, M., Podlogar, F., & Šibanc, R. (2008). Evolutionary artificial neural networks as tools for predicting the internal structure of microemulsions. *Journal of Pharmacy & Pharmaceutical Sciences*. https://doi.org/10.18433/J3F594

63. Amani, A., York, P., Chrystyn, H., et al. (2008). Determination of factors controlling the particle size in nanoemulsions using artificial neural networks. *European Journal of Pharmaceutical Sciences, 35*, 42–51. https://doi.org/10.1016/j.ejps.2008.06.002

64. Seyedhassantehrani, N., Karimi, R., Tavoosidana, G., & Amani, A. (2017). Concurrent study of stability and cytotoxicity of a novel nanoemulsion system: An artificial neural

networks approach. *Pharmaceutical Development and Technology, 22*, 383–389. https://doi.org/10.1080/10837450.2016.1212878

65. Charman, S. A., Charman, W. N., Rogge, M. C., et al. (1992). Self-emulsifying drug delivery systems: Formulation and biopharmaceutic evaluation of an investigational lipophilic compound. *Pharmaceutical Research, 9*, 87–93. https://doi.org/10.1023/a:1018987928936